Latest Breaking News On - க்ளென் சால்தான் - Page 6 : comparemela.com

Results: Glenmark Pharma Q4 net profit up 6% at Rs 233 87 cr

Results: Glenmark Pharma Q4 net profit up 6% at Rs 233 87 cr
freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.

Glenn saldanhaGlenmark pharmaceuticalsPharmaceuticals chairmanGlenmark pharmaGlenmark pharma q4க்ளென் சால்தான்க்ளேண்மர்க் மருந்துகள்மருந்துகள் தலைவர்க்ளேண்மர்க் பார்மா

Glenmark Q4 net profit up 6% at ₹233 87 cr - The Hindu BusinessLine

The drug maker’s brand FabiFlu has been at the forefront of the fight against Covid-19

Glenn saldanhaGlenmark pharmaceuticalsPharmaceuticals chairmanNet profitConsolidated revenue from operationsCovid 19க்ளென் சால்தான்க்ளேண்மர்க் மருந்துகள்மருந்துகள் தலைவர்நிகர ப்ராஃபிட்சர்வதேச பரவல்

Chief Executive Officer Alessandro Riva, M D , To Leave Ichnos Sciences

Share this article Share this article NEW YORK, May 21, 2021 /PRNewswire/ Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today announced that Alessandro Riva, M.D., will be leaving Ichnos effective August 15, 2021. We want to thank Dr. Riva for his visionary leadership as the first CEO of Ichnos. His strategic and scientific drive have given Ichnos a solid foundation to create and develop new medicines for patients. We wish him well in his future endeavors. Effective immediately, Cyril Konto, M.D., is appointed interim CEO and Alessandro Riva will provide transition assistance and support. Cyril is an oncologist by training, with 15 years of experience in the development of cancer immunotherapies, and he held positions of increasing responsibility at Allogene Therapeutics, Pfizer, and Bristol Myers Squibb before joining Ichnos. He will work with the Ichnos Board of Directors and other members

New yorkUnited statesCyril kontoAlessandro rivaGlenn saldanhaIchnos sciences incIchnos sciencesBristol myers squibbAllogene therapeuticsIchnos boardGlenmark boardsபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்சிரில் கொண்டோAlessandro ரீவக்ளென் சால்தான்

FabiFlu: Anti-Covid drug now top-selling pharma brand

MUMBAI: Call it the Covid effect. Anti-viral drug Favipiravir, used for Covid-19 treatment, has rocketed to the rank of the largest-selling pharma brand in April for the first time ever in the domestic retail market. The drug, marketed by Mumbai-based Glenmark as Fabiflu, posted sales of Rs 352 crore in April alone, overtaking sales of drugs for lifestyle ailments such as diabetes, which have long dominated the market. In April, Fabiflu overtook sales of other top-selling drugs being used in Covid-19 therapy, including health supplement Zincovit and pain-killer Dolo. Fabiflu mops up Rs 762crore sales in last 12 months During the pandemic, the top pecking order witnessed a change with Zincovit becoming the largestselling pharma brand in October last year, while others like Monocef, Dolo and Betadine grew at a strong clip this year.

Sun pharmaGlenn saldanhaMd glenmark pharmaceuticalsMumbai based glenmarkLasa supergenericsசூரியன் பார்மாக்ளென் சால்தான்மும்பை அடிப்படையிலானது க்ளேண்மர்க்

FabiFlu numero uno in Indian pharma market, show April sales data

Favipiravir brand FabiFlu from Glenmark has catapulted to capture the number one slot in the domestic pharma market in April – from 169th in February. With sales of Rs 352 crore in April, this brand alone accounted for over 2 per cent of the total domestic pharma market sales of Rs 15,662 crore. According to data from market research firm AIOCD AWACS, FabiFlu clocked sales of Rs 351.9 crore in April, a more than seven-fold jump from March. The second ranking brand Monocef, an antibiotic, clocked sales of Rs 112.9 crore, while the third brand Zincovit registered sales worth Rs 94.8 crore. The huge jump in FabiFlu sales happened owing to a surge in Covid cases during the month. Daily fresh cases touched 401,993 on April 30.

Glenn saldanhaக்ளென் சால்தான்